{"id":"veligrotug-vrdn-001","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased heart rate"},{"rate":null,"effect":"Thyroid hormone-related effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"THR-β agonists preferentially activate the beta isoform of the thyroid hormone receptor, which is highly expressed in the liver and plays a key role in lipid metabolism. By selectively activating THR-β, veligrotug increases the clearance of LDL cholesterol and reduces triglyceride levels while minimizing systemic thyroid hormone effects that could cause cardiac or metabolic side effects associated with non-selective thyroid hormone therapy.","oneSentence":"Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:50.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT06021054","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2023-11-14","conditions":"Thyroid Eye Disease","enrollment":188},{"nctId":"NCT05176639","phase":"PHASE3","title":"A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )","status":"COMPLETED","sponsor":"Viridian Therapeutics, Inc.","startDate":"2021-12-03","conditions":"Thyroid Eye Disease","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","companyName":"Viridian Therapeutics, Inc.","companyId":"viridian-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides. Used for Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}